February 15, 2018 (Vol. 38, No. 4)


The ResistancePlus™ MG qPCR test detects the sexually transmitted bacterium Mycoplasma genitalium along with the genetic SNPs that confer resistance to macrolide antibiotics, including azithromycin, the front-line antibiotic treatment of choice. ResistancePlus MG will potentially be a first-to-market molecular diagnostic test in the U.S., providing both detection of the MG infection along with information about antibiotic resistance of the disease.  The test has received regulatory clearances in Europe, Australia, and New Zealand. MDx PCR technology is the only such technology that allows simultaneous detection of infections and antibiotic resistance to infections. The company also has a similar test in development for gonorrhea. This product is not currently for sale in the U.S., but the company anticipates a 2018 launch.

Previous articleSmart Contacts Can Monitor the Glucose in Tears
Next articleNIH Budget Proposal